Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001181431-11-057267)

Filing Details

Accession Number:
0001181431-11-057267
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-11-22 13:24:03
Reporting Period:
2011-11-21
Filing Date:
2011-11-22
Accepted Time:
2011-11-22 13:24:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1466301 Clovis Oncology Inc. CLVS Pharmaceutical Preparations (2834) 900475355
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1479386 Ravi Viswanathan 1954 Greenspring Drive
Suite 600
Timonium MD 21093		 No No Yes No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-11-21 1,726,248 $0.00 1,726,248 No 4 C Indirect See Note 2
Common Stock Acquisiton 2011-11-21 377,124 $0.00 2,103,372 No 4 C Indirect See Note 2
Common Stock Acquisiton 2011-11-21 1,316,299 $13.00 3,419,671 No 4 P Indirect See Note 2
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Note 2
No 4 C Indirect See Note 2
No 4 P Indirect See Note 2
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1 Preferred Stock Disposition 2011-11-21 1,186,897 $0.00 409,274 $0.00
Common Stock Series A-2 Preferred Stock Disposition 2011-11-21 1,206,897 $0.00 416,171 $0.00
Common Stock Series B Preferred Stock Disposition 2011-11-21 2,612,330 $0.00 900,803 $0.00
Common Stock 5% Convertible Note due 2012 Disposition 2011-11-21 377,124 $0.00 377,124 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock, on a 2.9 for 1 basis (inadvertently reported as a 1 for 1 basis on Form 3, filed November 15, 2011), immediately prior to the closing of the Issuer's initial public offering on November 21, 2011 and had no expiration date.
  2. The Reporting Person is a director of NEA 13 GP, LTD ("NEA 13 LTD"), the sole general partner of NEA Partners 13, L.P., ("NEA Partners 13"), the sole general partner of New Enterprise Associates 13, L.P. ("NEA 13"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Reporting Person has no pecuniary interest.
  3. The outstanding principal and accrued and unpaid interest on the Convertible Notes automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering at the Issuer's initial public offering price per share.
  4. The Reporting Person is a director of NEA 13 LTD, the sole general partner of NEA Partners 13, the sole general partner of NEA 13, which is the holder of the Convertible Notes. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the Convertible Notes in which the Reporting Person has no pecuniary interest.